ARCHIVE OF OLDER REPORTS AND DEVELOPMENTS
(Before March 2000)

MARCH & APRIL 2000:

• 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, January 30-February 2, 2000  (3/23/2000)

• Liver-Specific Alpha 2 Interferon Gene Expression Results in Protection from Induced Hepatitis (4/29/2000)

• Therapy Interruptions and New Data Reported at the Salvage Therapy Workshop (4/29/2000)

• A Mutation in Human Immunodeficiency Virus Type 1 Protease, N88S, That Causes In Vitro Hypersensitivity to Amprenavir (4/20/2000)

• Anti-Human Immunodeficiency Virus Type 1 (HIV-1) CD8+ T-Lymphocyte Reactivity during Combination Antiretroviral Therapy in HIV-1-Infected Patients with Advanced Immunodeficiency (4/20/2000)

• Evidence for Viral Virulence as a Predominant Factor Limiting Human Immunodeficiency Virus Vaccine Efficacy (4/19/2000)

• U.S. Food and Drug Administration Grants Expedited Review To Roche for First PCR-Based Tests to Detect Hepatitis C Virus (4/19/2000)  

• Hepatic Fibrosis Regresses in Interferon-Responsive Hepatitis C Patients (4/17/2000) 

• STUDY SUGGESTS LOSS OF HEPATITIS B ANTIGEN INCREASES WITH LENGTH OF TREATMENT WITH EPIVIR-HBV (4/17/2000)    

• Long-Term Incidence of Hepatitis B Virus Resistance to Lamivudine in Human Immunodeficiency Virus-Infected Patients (4/17/2000) 

• Interferon in HBV/HIV Coinfection; Serum Alanine Transaminase Level Is a Good Predictor of Response to Interferon Alfa Therapy for Chronic Hepatitis B in Human Immunodeficiency Virus-Infected Patients (4/17/2000) 

• 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, January 30-February 2, 2000 (3/23/2000) 

• NATAP REPORTS, December 1999,
  HIV and Hepatitis C Conference Reports from:

• Resistance Workshop - June 1999, San Diego
• First Lipodystrophy Conference - June 1999, San Diego
• ICAAC - September 1999, San Francisco

• 7th European Conference on Clinical Aspects and Treatment of HIV,
  October 1999, Lisbon

• AASLD - American Association for the Study of Liver Disease, Dallas, November 1999

• IDSA - November, 1999 (3/23/2000)

• The ART of Treating HIV/Hepatitis Co-infection: NATAP's 8th Community Education Forum, Friday,  Feb. 18th, 2000, Click here to see the archive of its live broadcast over the internet (2/18/2000)

• Natural History of Hepatitis C Virus Carriers With Persistently Normal Aminotransferase Levels (4/3/2000)

• Hepatitis C Immunology (4/3/2000)

• Host genetic factors influence disease progression in chronic hepatitis C (4/3/2000)

• Interleukin 10 Treatment Reduces Fibrosis in Patients With Chronic Hepatitis C: A Pilot Trial of Interferon Nonresponders (4/3/2000)

• HIV Sexual Transmission Factors: viral load, circumcision (3/30/2000)

• AIDS Is Killer for African-American Men & Women 25-44 (2/29/2000)

• Hepatitis C Transmission and Pregnancy (2/29/2000)

• New HCV Treatment in Early Development--Ribozymes; Inhibition of Hepatitis C Virus (HCV)-RNA-Dependent Translation and Replication of a Chimeric HCV Poliovirus Using Synthetic Stabilized Ribozymes (3/20/2000)

• Transmission Rate of HCV to Newborn 5%; Prevalence and Clinical Course of Chronic Hepatitis C Virus (HCV) Infection and Rate of HCV Vertical Transmission in a Cohort of 15,250 Pregnant Women (3/20/2000)

• CTLs and Response to HCV Therapy (3/20/2000)

• Long-term administration of interferon-alpha in non-responder patients with chronic hepatitis C: follow-up of liver fibrosis over 5 years;  Improved Fibrosis Seen with Long-Term treatment (>1 year) in Cirrhotic Patients in IFN Non-Responders (3/5/2000)

• Hepatitis B Genotypes Correlate With Clinical Outcomes in Patients With Chronic Hepatitis B (2/14/2000)

• When to begin therapy; excerpts and comments from articles written by Keith Henry, MD, and Oren Cohen, MD, in recent medical journals (3/5/2000)